MA55964A - Agents inhibiteurs de la tyrosine kinase de bruton - Google Patents
Agents inhibiteurs de la tyrosine kinase de brutonInfo
- Publication number
- MA55964A MA55964A MA055964A MA55964A MA55964A MA 55964 A MA55964 A MA 55964A MA 055964 A MA055964 A MA 055964A MA 55964 A MA55964 A MA 55964A MA 55964 A MA55964 A MA 55964A
- Authority
- MA
- Morocco
- Prior art keywords
- bruton
- tyrosine kinase
- kinase inhibitors
- inhibitors
- tyrosine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962847985P | 2019-05-15 | 2019-05-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA55964A true MA55964A (fr) | 2022-03-23 |
Family
ID=70978601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA055964A MA55964A (fr) | 2019-05-15 | 2020-05-15 | Agents inhibiteurs de la tyrosine kinase de bruton |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220259194A1 (fr) |
| EP (1) | EP3969124A1 (fr) |
| JP (1) | JP2022532235A (fr) |
| MA (1) | MA55964A (fr) |
| WO (1) | WO2020232330A1 (fr) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| SG10201908558WA (en) | 2013-12-11 | 2019-10-30 | Biogen Ma Inc | Biaryl Compounds Useful For The Treatment Of Human Diseases In Oncology, Neurology And Immunology |
| ES2713196T3 (es) | 2013-12-11 | 2019-05-20 | Biogen Ma Inc | Compuestos de biarilo útiles para el tratamiento de enfermedades humanas en oncología, neurología e inmunología |
| PE20181073A1 (es) * | 2015-12-17 | 2018-07-04 | Gilead Sciences Inc | Compuestos inhibidores de la quinasa de union a tank |
| JOP20190233A1 (ar) * | 2017-04-14 | 2019-10-02 | Biogen Ma Inc | نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون |
-
2020
- 2020-05-15 WO PCT/US2020/033051 patent/WO2020232330A1/fr unknown
- 2020-05-15 JP JP2021568241A patent/JP2022532235A/ja active Pending
- 2020-05-15 US US17/610,963 patent/US20220259194A1/en active Pending
- 2020-05-15 MA MA055964A patent/MA55964A/fr unknown
- 2020-05-15 EP EP20730834.7A patent/EP3969124A1/fr active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220259194A1 (en) | 2022-08-18 |
| JP2022532235A (ja) | 2022-07-13 |
| WO2020232330A8 (fr) | 2020-12-24 |
| WO2020232330A1 (fr) | 2020-11-19 |
| EP3969124A1 (fr) | 2022-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201903932B (en) | Imidazopyrazine inhibitors of bruton's tyrosine kinase | |
| DK3265084T3 (da) | Farmaceutiske formuleringer af Bruton's tyrosinkinase-hæmmer | |
| MA51616A (fr) | Inhibiteurs d'adn-pk | |
| MA51619A (fr) | Inhibiteurs de la protéine kinase dépendante de l'adn | |
| IL255831A (en) | Inhibitors of bruton's tyrosine kinase | |
| MA41350A (fr) | Synthèse d'un inhibiteur de la tyrosine kinase de bruton | |
| ZA201906887B (en) | Bruton's tyrosine kinase inhibitors | |
| EP3414234A4 (fr) | Inhibiteurs de la tyrosine kinase de bruton | |
| EP3405192A4 (fr) | Inhibiteurs de la tyrosine kinase de bruton | |
| MA52629A (fr) | Agents inhibiteurs de la tyrosine kinase de bruton | |
| HK1258699A1 (zh) | 包含酪氨酸蛋白激酶抑制劑的劑型組合物 | |
| ZA201903694B (en) | Inhibitors of bruton's tyrosine kinase | |
| MA52004A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase | |
| MA41828A (fr) | Co-cristaux d'un inhibiteur de la tyrosine kinase de bruton | |
| MA41827A (fr) | Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton | |
| MA50013A (fr) | Analogues de benzoazépine utilisés en tant qu'agents inhibiteurs de la tyrosine kinase de bruton | |
| MA42510A (fr) | Formes et compositions d'inhibiteurs biaryles de la tyrosine kinase de bruton | |
| EP3543239A4 (fr) | Inhibiteur sélectif de la tyrosine kinase de bruton et son utilisation | |
| IL284916A (en) | Cyclic molecules as Bruton's tyrosine kinase inhibitors | |
| MA42509A (fr) | Formes d'adipate et compositions d'inhibiteurs de biaryle de la tyrosine kinase de bruton | |
| EP3882241A4 (fr) | Inhibiteur de la tyrosine kinase de bruton | |
| MA53648A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase | |
| KR102668958B9 (ko) | 브루톤 티로신 키나아제 억제제인 치환된 1-아미노-1h-이미다졸-5-카르복사미드 | |
| MA55964A (fr) | Agents inhibiteurs de la tyrosine kinase de bruton | |
| EP3412657A4 (fr) | Nouvel inhibiteur irréversible de la tyrosine kinase de bruton |